TPTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TPTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
For the three months ended in Jun. 2022, Turning Point Therapeutics spent $1.53 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $29.75 Mil on purchasing investments. It gained $108.22 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Turning Point Therapeutics gained $76.94 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Jun. 2022.
The historical data trend for Turning Point Therapeutics's Cash Flow from Investing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Turning Point Therapeutics Annual Data | |||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | ||||||
Cash Flow from Investing | -0.09 | -0.30 | -361.08 | -210.03 | 5.46 |
Turning Point Therapeutics Quarterly Data | |||||||||||||||||||
Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | |
Cash Flow from Investing | Get a 7-Day Free Trial | -8.27 | 17.44 | 75.22 | -60.41 | 76.94 |
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).
Likewise, if a company buys another company for cash, this will reduce their cash position.
Turning Point Therapeutics's Cash Flow from Investing for the fiscal year that ended in Dec. 2021 is calculated as:
Cash Flow from Investing | (A: Dec. 2021 ) | ||||
= | Purchase Of Property, Plant, Equipment | + | Sale Of Property, Plant, Equipment | + | Purchase Of Business |
= | -2.427 | + | 0 | + | 0 |
+ | Sale Of Business | + | Purchase Of Investment | + | Sale Of Investment |
+ | 0 | + | -439.23 | + | 447.119 |
+ | Net Intangibles Purchase And Sale | + | Cash From Discontinued Investing Activities | + | Cash From Other Investing Activities |
+ | 0 | + | 0 | + | 0 |
= | 5.46 |
Turning Point Therapeutics's Cash Flow from Investing for the quarter that ended in Jun. 2022 is calculated as:
Cash Flow from Investing | (Q: Jun. 2022 ) | ||||
= | Purchase Of Property, Plant, Equipment | + | Sale Of Property, Plant, Equipment | + | Purchase Of Business |
= | -1.527 | + | 0 | + | 0 |
+ | Sale Of Business | + | Purchase Of Investment | + | Sale Of Investment |
+ | 0 | + | -29.754 | + | 108.22 |
+ | Net Intangibles Purchase And Sale | + | Cash From Discontinued Investing Activities | + | Cash From Other Investing Activities |
+ | 0 | + | 0 | + | 0 |
= | 76.94 |
Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $109.19 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Turning Point Therapeutics (NAS:TPTX) Cash Flow from Investing Explanation
Cash flow from investing contains nine items:
1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.
Turning Point Therapeutics's purchase of property, plant, equipment for the three months ended in Jun. 2022 was $-1.53 Mil. It means Turning Point Therapeutics spent $1.53 Mil on purchasing property, plant, equipment.
In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.
In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.
Turning Point Therapeutics's sale of property, plant, equipment for the three months ended in Jun. 2022 was $0.00 Mil. It means Turning Point Therapeutics gained $0.00 Mil from selling property, plant, and equipment.
3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.
Turning Point Therapeutics's purchase of business for the three months ended in Jun. 2022 was $0.00 Mil. It means Turning Point Therapeutics spent $0.00 Mil on purchasing business.
4. Sale Of Business:
Sale of business indicates the amount gained from selling business.
Turning Point Therapeutics's sale of business for the three months ended in Jun. 2022 was $0.00 Mil. It means Turning Point Therapeutics gained $0.00 Mil from selling business.
5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.
Turning Point Therapeutics's purchase of investment for the three months ended in Jun. 2022 was $-29.75 Mil. It means Turning Point Therapeutics spent {stock_data.stock.currency_symbol}}29.75 Mil on purchasing investments.
6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.
Turning Point Therapeutics's sale of investment for the three months ended in Jun. 2022 was $108.22 Mil. It means Turning Point Therapeutics gained $108.22 Mil from selling investments.
7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.
Turning Point Therapeutics's net Intangibles purchase and sale for the three months ended in Jun. 2022 was $0.00 Mil. It means Turning Point Therapeutics paid $0.00 Mil for net Intangibles purchase and sale.
8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.
Turning Point Therapeutics's cash from discontinued investing activities for the three months ended in Jun. 2022 was 0.00 Mil. It means Turning Point Therapeutics paid $0.00 Mil for discontinued investing activities.
9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.
Turning Point Therapeutics's cash from other investing activities for the three months ended in Jun. 2022 was $0.00 Mil. It means Turning Point Therapeutics paid $0.00 Mil for other investing activities.
Thank you for viewing the detailed overview of Turning Point Therapeutics's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.
Paolo Tombesi | officer: EVP & Chief Financial Officer | 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807 |
Steve M Sabus | officer: SVP & Chief Commercial Officer | 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121 |
Brian Sun | officer: SVP & General Counsel | C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121 |
Mohammad Hirmand | officer: EVP and Chief Medical Officer | C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105 |
Athena Countouriotis | director, officer: President & CEO | C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121 |
Siegfried Reich | officer: EVP & Chief Scientific Officer | 10505 ROSELLE STREET SAN DIEGO CA 92121 |
Andrew John Partridge | officer: EVP & Chief Commercial Officer | C/O CENTREXION THERAPEUTICS CORPORATION 200 STATE STREET BOSTON MA 02109 |
Annette North | officer: EVP, General Counsel & Secty. | C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121 |
Mark J Alles | director | C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
Van Hoose Kyri K. | officer: Principal Accounting Officer | C/O TURNING POINT THERAPEUTICS, INC., 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121 |
Barbara W. Bodem | director | C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277 |
Brian Lee Baker | officer: VP of Finance and Admin. | C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DR., STE. 225 SAN DIEGO CA 92121 |
Yi Larson | officer: EVP & Chief Financial Officer | C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121 |
Jingrong Jean Cui | director, 10 percent owner, officer: Chief Scientific Officer | C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DR., STE. 225 SAN DIEGO CA 92121 |
Simeon George | director | 161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 07-04-2022
By PurpleRose PurpleRose • 07-15-2022
By PRNewswire PRNewswire • 07-13-2022
By GuruFocusNews GuruFocusNews • 06-29-2022
By GuruFocusNews GuruFocusNews • 07-05-2022
By PRNewswire PRNewswire • 06-30-2022
By PurpleRose PurpleRose • 08-08-2022
By PurpleRose PurpleRose • 07-14-2022
By GuruFocusNews GuruFocusNews • 07-05-2022
By GuruFocusNews GuruFocusNews • 07-02-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.